Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One (2017) 0.75

The price of innovation: new estimates of drug development costs. J Health Econ (2003) 23.43

Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics (2010) 3.08

Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ (2003) 2.50

Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) (2004) 2.33

Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health (2010) 2.04

International prices and availability of pharmaceuticals in 2005. Health Aff (Millwood) (2008) 1.54

Factors influencing global antiretroviral procurement prices. BMC Public Health (2009) 1.16

Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ (2013) 1.06

Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings. Health Policy Plan (2009) 0.89

Profit, payment and pharmaceutical practices: perspectives from hospitals in Bangkok. Health Policy (1999) 0.88

The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff (Millwood) (2011) 0.81

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol (2009) 7.67

Cost of stroke in the United Kingdom. Age Ageing (2009) 4.82

The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ (2010) 3.95

The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail (2002) 3.17

Equity, waiting times, and NHS reforms: retrospective study. BMJ (2009) 2.86

An economic evaluation of lung transplantation. J Thorac Cardiovasc Surg (2002) 2.29

QALYs: the basics. Value Health (2009) 1.99

Income-related inequalities in the prevalence of depression and suicidal behaviour: a 10-year trend following economic crisis. World Psychiatry (2011) 1.39

Toward a consensus on the QALY. Value Health (2009) 1.30

Cost-effectiveness of stroke unit care followed by early supported discharge. Stroke (2008) 1.25

In search of a corrected prescription drug elasticity estimate: a meta-regression approach. Health Econ (2007) 0.94

A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc (2010) 0.93

In defence of our research on competition in England's National Health Service. Lancet (2011) 0.92

Persistence despite action? Measuring the patterns of health inequality in England (1997-2007). Health Policy (2011) 0.87

Stochastic demand, production responses and hospital costs. J Health Econ (2003) 0.87

Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines. Am J Manag Care (2003) 0.85

An assessment of the cost of percutaneous pulmonary valve implantation (PPVI) versus surgical pulmonary valve replacement (PVR) in patients with right ventricular outflow tract dysfunction. J Med Econ (2011) 0.83

Is theatre utilization a valid performance indicator for NHS operating theatres? BMC Health Serv Res (2008) 0.83

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ (2012) 0.81

The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics (2003) 0.81

The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff (Millwood) (2011) 0.81

Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. Eur J Heart Fail (2011) 0.78

IQWiG methods--a response to two critiques. Health Econ (2010) 0.77

The influence of economic incentives and regulatory factors on the adoption of treatment technologies: a case study of technologies used to treat heart attacks. Health Econ (2009) 0.77

The European value-pricing game. Expert Rev Pharmacoecon Outcomes Res (2012) 0.75

Technology diffusion and substitution of medical innovations. Adv Health Econ Health Serv Res (2012) 0.75

Professor Gavin Mooney 1943-2012. Health Econ (2013) 0.75

Publication selection in health policy research: the winner's curse hypothesis. Health Policy (2012) 0.75

More money for medical research. BMJ (2006) 0.75